BenchSci lands Series B

BenchSci, which uses machine learning to identify and resolve preclinical research inefficiencies in drug discovery, has raised US$22 million in Series B financing.

Toronto-based BenchSci, which uses machine learning to identify and resolve preclinical research inefficiencies in drug discovery, has raised US$22 million in Series B financing. F-Prime Capital led the round. As part of the deal, Shervin Ghaemmaghami, senior vice president of F-Prime, will join BenchSci’s board of directors.

Source: Press Release